[Yanzhou Coal Mining Company Limited Date Zhang Baocai Director THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt If you have sold or transferred Yanzhou Coal Mining Company Limited YANZHOU COAL MINING COMPANY LIMITED (A joint stock limited company incorporated in the Peoples Republic of China with limited liability) (Stock Code: 1171) (1) PROPOSED]
[ORIGIN AGRITECH NAMES NEW PRESIDENT & CEO Board of Directors appoints Dr. William S. Niebur to grow business, lead strategic entry into global market April 25, 2016 – Beijing, CHINA – Dr. Niebur takes the reins of the company at a time when Origin is strategically positioning itself as a global participant in the biotechnology and seed market. Origin will] []
[Yanzhou Coal Mining Company Limited Date Zhang Baocai Director THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt If you have sold or transferred Yanzhou Coal Mining Company Limited YANZHOU COAL MINING COMPANY LIMITED (A joint stock limited company incorporated in the Peoples Republic of China with limited liability) (Stock Code: 1171) (1) PROPOSED]
[ORIGIN AGRITECH NAMES NEW PRESIDENT & CEO Board of Directors appoints Dr. William S. Niebur to grow business, lead strategic entry into global market April 25, 2016 – Beijing, CHINA – Dr. Niebur takes the reins of the company at a time when Origin is strategically positioning itself as a global participant in the biotechnology and seed market. Origin will] []
[CNOOC Limited Jiewen Li]
[CNOOC Limited Jiewen Li]
[Page 1.1 Announcement in relation to appointments of Chairman and Chief Executive Officer as well as President and Chief Operating Officer, dated April 25, 2016 A-1 our business and operating strategies and our ability to successfully execute these strategies; our network expansion and capital expenditure plans; our operations and business prospects; the expected benefit of any]
[Page 1.1 Announcement in relation to appointments of Chairman and Chief Executive Officer as well as President and Chief Operating Officer, dated April 25, 2016 A-1 our business and operating strategies and our ability to successfully execute these strategies; our network expansion and capital expenditure plans; our operations and business prospects; the expected benefit of any]
[Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 56,906,561 common shares as of December 31, 2015 ¨ x ¨ x x ¨ x ¨ o Large accelerated filer x Accelerated filer o Non-accelerated filer x U.S. GAAP International Financial] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Sinovac Biotech Co., Ltd., a PRC company 3. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 4. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company 5. Sinovac Biomed Co., Ltd. (formerly known as Sinovac Zhong] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER I, Nan Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Weidong Yin Chief Executive Officer] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Nan Wang Chief Financial Officer] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: i) Registration Statement (Form S-8 No. 333-161827) pertaining to Sinovac Biotech Ltd.’s 2003 Stock Option Plan; and ii) Registration Statement (Form S-8 No. 333-190980) pertaining to Sinovac Biotech Ltd.’s 2012 Share Incentive Plan; of our reports dated April 25, 2016, with]
[Alibaba Group Announces the Results of a Non-Disciplinary Review by the Hong Kong Takeovers and Mergers Panel The Hong Kong Takeovers and Mergers Panel (the Panel) ruled on April 23, 2016 in a non-disciplinary review of Alibaba Groups 2014 investment into CITIC 21CN Company Limited (HKSE stock code: 241), which was re-named Alibaba Health Information Technology Limited (Alibaba Health), that] [2 ALIBABA GROUP HOLDING LIMITED]
